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ABSTRACT
Tracheal replacement for the treatment of end-stage airway disease remains an elusive goal. The
use of tissue-engineered tracheae in compassionate use cases suggests that such an approach is a
viable option. Here, a stem cell-seeded, decellularized tissue-engineered tracheal graft was used
on a compassionate basis for a girl with critical tracheal stenosis after conventional reconstructive
techniques failed. The graft represents the ﬁrst cell-seeded tracheal graft manufactured to full
good manufacturing practice (GMP) standards. We report important preclinical and clinical data
from the case, which ended in the death of the recipient. Early results were encouraging, but an
acute event, hypothesized to be an intrathoracic bleed, caused sudden airway obstruction 3 weeks
post-transplantation, resulting in her death. We detail the clinical events and identify areas of pri-
ority to improve future grafts. In particular, we advocate the use of stents during the ﬁrst few
months post-implantation. The negative outcome of this case highlights the inherent difﬁculties in
clinical translation where preclinical in vivo models cannot replicate complex clinical scenarios that
are encountered. The practical difﬁculties in delivering GMP grafts underscore the need to reﬁne
protocols for phase I clinical trials. STEM CELLS TRANSLATIONAL MEDICINE 2017;6:1458–1464
SIGNIFICANCE STATEMENT
We present a compassionate use case of tracheal tissue engineering using a cell-seeded,
decellularized donor trachea. The case involved application of full good manufacturing practice
standards to create a manufactured advanced medical product for transplantation.
INTRODUCTION
Congenital tracheal stenosis is rare and causes
severe airway compromise due to the presence of
complete tracheal rings. Surgical approaches with
patch tracheoplasty augment the trachea but
often fail in the long term because of re-stenosis
[1]. Over the past decade, slide tracheoplasty has
become the mainstay of treatment, as it signiﬁ-
cantly improves morbidity and mortality over
other surgical reconstruction techniques [2, 3].
However, despite these advances in reconstruc-
tive surgery, there are still children, teenagers,
and adults with advanced disease that are beyond
the reach of conventional therapy and for whom
only palliation is possible [4]. Thus, alternative
strategies for these rare and, on occasion, life-
threatening cases are necessary.
Tracheal replacement therapy has been pro-
posed as a solution for patients with severe end-
stage disease [5]. In children, reconstruction with
a cadaveric trachea homograft is feasible and, in
short-segment (cervical) disease, short-term to
medium-term results have been encouraging. It is
unclear if the same outcomes apply to long-
segment disease [6]. Additionally, homografts
have procurement difﬁculties and are currently
unregulated. Allotransplantation also involves
long-term immunosuppression with the concomi-
tant risks. The use of tissue-engineered grafts
based on synthetic scaffolds offers theoretical
advantages, although ﬁrst results have proven
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generally disappointing [7, 8], in part as a result of their failure to
integrate with recipient tissue. Meanwhile, tissue-engineered
grafts based on decellularized scaffold constructs have remained
under consideration [9–11].
Clinical applications of tissue-engineered hollow organ
constructs have been reported by a number of groups. Atala and
colleagues partially reconstructed a bladder with a collagen-
polyglycolic acid scaffold seeded with urothelial and muscle cells
expanded in culture from biopsy [12]. Although initial reports
have been encouraging, a larger clinical trial was interrupted due
to a high incidence of adverse effects [13]. Airway constructs
based on both decellularized (“biologic”) and synthetic scaffolds
have been transplanted in adults for compassionate reasons in
association with respiratory epithelial cells and variably differenti-
ated mesenchymal stromal cells (MSCs). However, protocols vary
widely, products have not been manufactured as advanced medi-
cines to good manufacturing practice (GMP) compliance (U.K.;
cGMP in the U.S.), outcome reports have been limited, and some
aspects of these cases are controversial [9, 14].
Initial reports suggest optimism for reconstructing airways by
tissue engineering approaches, but data on long-term outcomes
are still scarce. The ﬁrst adult transplanted with an autologous
bone marrow MSC-derived chondrocyte and autologous respira-
tory epithelial cell-seeded decellularized scaffold has a ﬁve-year
follow-up report [10, 14]. We previously reported the four-year
follow-up outcome of a child transplanted with an autologous
cell-seeded tissue-engineered construct, combined with the
use of exogenous growth factors at the time of the procedure
[11, 15].
Here, we describe GMP methods developed to produce a
decellularized tracheal scaffold seeded with autologous cells as an
advanced medicine speciﬁcally for compassionate use in a teen-
age girl after extensive multidisciplinary team discussion. We
describe the adverse clinical outcome in order to add construc-
tively to the published literature relating to tissue-engineered air-
ways and use our experience of this case to provide hypotheses
for future research and emphasize the need for transparent, for-
mal clinical trials. We feel that it is essential that all such relevant
cases reach the readership.
MATERIALS AND METHODS
The Recipient
A girl, born with a single left lung and long-segment congenital tra-
cheal stenosis (Fig. 1A), underwent a tracheoplasty with a lateral
costal cartilage graft repair at 2 months of age. Following surgery,
failure to extubate and ongoing malacia prompted immediate
insertion of balloon-expandable stainless steel stents (Palmaz
stent, Cordis Corporation, Miami Lakes, FL, https://www.cordis.
com/en_us.html; Fig. 1B). This allowed her to be extubated with
mild intermittent positive pressure ventilatory support. Proactive
management of stents was performed with endoscopic monitor-
ing and balloon dilatation as required. At 4 years of age, the child
underwent a pericardial patch tracheoplasty due to recurrent ste-
nosis following failed serial balloon dilatations. Incomplete
removal of the stents resulted in recurrent granulation tissue for-
mation and re-stenosis along the length of the repaired trachea,
which was conservatively managed (Fig. 1C and 1D). Eventually, a
tracheostomy was necessary, and the child became bilevel positive
airway pressure (BiPAP) ventilation-dependent at night.
Figure 1. Preoperative evaluation of the airway demonstrating long-
segment tracheal stenosis with a single lung. (A): Three-dimensional
(3D) model of the tracheobronchial tree demonstrating extent of steno-
sis (arrow) and tortuous trachea with trifurcation of the airway. (B): 3D
model (left) of the trachea demonstrating multiple stents (cyan) and
their relation to the stenosis (arrows); corresponding bronchogram
(right). (C): Endoscopic photograph of the airway at the level of subglot-
tis (left) and at the stenosis (right). White arrow indicates granulation
tissue. (D): Preoperative computed tomography angiogram demonstrat-
ing stenotic trachea with stent in relation to arch of aorta. Blue asterisk
demonstrates stent location; red hashtag indicates arch of aorta.
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At 15 years of age, she suffered a home respiratory arrest but
was successfully resuscitated. Clinical deterioration, combined
with the potential for further respiratory arrests, prompted clinical
teams to consider tracheal replacement therapy in the absence of
a satisfactory conventional reconstructive option. The child was
referred to and assessed at Great Ormond Street Hospital for Chil-
dren (GOSH; London, U.K.) by the multidisciplinary (“tracheal”)
team, licensed by U.K. Specialist Commissioners for tracheal
reconstructions in children. The multidisciplinary team was as pre-
viously described [16], with additional representation from clini-
cians and scientists familiar with graft and cell manufacture
protocols. Consideration was given to alternate strategies, includ-
ing palliation and preserved homograft replacement. Given the
group’s previous experience and success with autologous stem
cell-based tracheal transplant [11, 15], a tissue-engineered con-
struct was offered to the child and her family. The time course of
her deterioration permitted procurement of a donor trachea for
GMP-compliant decellularization and concomitant expansion of
autologous MSCs and epithelial cells in a fully licensed cell therapy
facility (The Centre for Cell, Gene and Tissue Therapeutics, Royal
Free Hospital and University College London, London, U.K.) for
autologous reseeding in a bioreactor ex vivo. After further multi-
disciplinary discussion, approval by the Clinical Ethics Committee
at GOSH and under licensing of the Human Tissue Authority (HTA)
and the Medicines and Healthcare Products Regulatory Agency
(MHRA, U.K. equivalent to the U.S. Food and Drug Administration
[FDA]), the child, family, and clinical team agreed to the procedure
with fully informed consent. The procedure took place in February
2012 at GOSH.
Pre-Transplant Preparation
The tracheal graft was a decellularized allogeneic trachea obtained
from a cadaveric donor and seeded ex vivo with cell culture-
expanded bone marrow-derived MSCs and nasal-derived epithe-
lial cells. In the European Union, scaffolds containing human cells
are regulated as tissue-engineered advanced therapeutic medici-
nal products (ATMPs). A major challenge was the implementation
of GMP-compliant production processes in order to satisfy regula-
tory requirements. This product was manufactured to GMP com-
pliance and released for implantation as an unlicensed medicine
under manufacturing authorization from the U.K. MHRA according
to predeﬁned release criteria (see supplemental online data).
The tracheal scaffold was derived from a human donor
obtained through the U.K. national transplant services (National
Health Services Blood and Transplant Tissue Services) under HTA
licensing, and the donor was screened for potential transplant-
transmissible diseases in accordance with European regulations.
The donor trachea was matched for normal tracheal diameter and
procured such that length would be in excess of the host diseased
segment.
The decellularization protocol applied to the trachea involved
detergent enzymatic processing under vacuum pressure as previ-
ously described [17, 18] but using equivalent, GMP-compliant
decellularization reagents. Brieﬂy, tissue was thawed to room tem-
perature over 24 hours. Decellularization was performed under
vacuum in a stainless steel Ricordi chamber with ports and a pres-
sure gauge to measure the vacuum (1 Torr). Decellularization
steps were all performed under vacuum on an orbital shaker at
140 rpm unless stated otherwise (supplemental online Fig. 4). The
trachea was incubated in detergent solution containing 0.25%
sodium deoxycholate, 0.25% TritonX-100 in Hank’s balanced salt
solution for 24 hours at 378C. This was followed by a wash step,
which consisted of two cycles of wash solution for 2 hours at 378C
and further incubation for 44 hours at 48C on an undulating
orbital shaker at 20 rpm. The trachea was then incubated in nucle-
ase solution at 378C for 24 hours, followed by wash steps, as
described above. The nuclease solution with wash steps was
repeated once, and the scaffold product was temporarily stored in
University of Wisconsin cold storage solution at 48C prior to cell
engraftment.
Autologous MSCs were obtained from a bone marrow aspi-
rate prior to graft production and expanded through four cell pas-
sages to obtain sufﬁcient MSCs for both quality control and
scaffold seeding (supplemental online Fig. 1). Similarly, respiratory
epithelial cells were obtained from mucosal biopsies obtained
from the nasal septum and inferior turbinate and expanded as
explant cultures. Cells were seeded onto the scaffold in a bioreac-
tor prior to transplantation (Fig. 2A and 2B; see supplemental
online data).
Tracheal Replacement Surgery
Following induction with general anesthesia, a redo sternotomy
was performed. Mobilization of an adherent single left lung was
required to obtain access to a right-sided heart. Following cannu-
lation of the aorta and inferior vena cava, hypothermic cardiopul-
monary bypass was commenced with full heparinization. The
trachea was densely adherent to adjacent structures, including
the aorta. It was mobilized thoroughly and resected to within
1 cm of the tracheostomy and 1 cm above the carina (Fig. 3A).
Partial migration of the stent through the tracheal wall meant it
was not possible to fully remove the metallic stent over the poste-
rior wall. Both proximal and distal ends of the replacement tra-
chea (Fig. 3B and 3C) were anastomosed with interrupted
horizontal mattress sutures (4/0 PDS II) and tested for an air leak
prior to weaning off bypass (Fig. 3D). Laparoscopic exploration of
the abdomen revealed insufﬁcient omentum to form a “wrap”
around the construct because of previous abdominal surgery,
including fundoplication and gastrostomy. Pleural and mediastinal
drains were inserted, and the sternum was closed in layers. The
tracheostomy tube was changed to size 5.0 Portex Bivona (Smiths
Medical, Ashford, U.K., https://www.smiths-medical.com). Postop-
erative antibiotics were given, including amikacin and teicoplanin.
RESULTS
Immediate postoperative bronchoscopy revealed the graft to be
patent and the anastomoses intact. The posterior trachealis wall
appeared to partially prolapse into the airway, but this was
improved by positive airway pressure (Fig. 4A). It was possible to
pass a ﬂexible bronchoscope (size 4.0 mm; Olympus Corporation,
Shinjuku, Tokyo, https://www.olympus-global.com) through the
graft to the carina. Post-surgery ventilator support was immedi-
ately provided through the tracheostomy but with minimal pres-
sure settings. The tracheostomy was downsized within 24 hours to
an uncuffed fenestrated tube.
The patient tolerated pureed foods with no signs of aspiration
and spoke in full sentences within 24 hours. She continued to
make good progress with decreasing ventilator support and non-
invasive positive pressure ventilation. Microlaryngoscopy and
bronchoscopy was used for graft monitoring and removal of
excess secretions and mucus plugs. Dynamic information via
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bronchography showed a patent airway with only mild malacia,
and so the tracheostomy was upsized to uncuffed 5.5 Bivona
tube. Minimal pressure support was required with positive end
expiratory pressure setting of 10/5 cmH2O. Humidiﬁed oxygen
with regular nebulizers was provided throughout with regular
chest physiotherapy. Initially, the patient mobilized without prob-
lems and walked distances greater than 100 meters, a distance
not previously possible for her. Monitoring of the airway
Figure 2. Strategy for delivering the cell-seeded decellularized trachea scaffold. (A): Donor respiratory epithelial cells were isolated from
mucosal biopsies taken from the nose and expanded by explant culture. Epithelial cells were passaged over 14 days prior to cryopreservation.
Bone marrow aspirate was also obtained, and MSCs were expanded in culture over the same time period before cryopreservation. Prior to
transplantation, cells were thawed and expanded for 7 days, seeded onto the decellularized scaffold in a bioreactor, and incubated for 48
hours. (B): Schematic representation of surgical strategy with implantation of the tracheal product in place of the diseased trachea. Abbreviation:
MSCs, mesenchymal stromal cells.
Figure 3. Surgical transplantation of a good manufacturing practice-compliant tissue-engineered tracheal product. (A): Macroscopic image
showing a representative segment of the resected trachea with stenosis. (B): Tracheal product immediately prior to transplantation. (C): Deliv-
ery of the cell-seeded decellularized tracheal scaffold under cardiopulmonary bypass. (D): Tracheal product in situ with arch of aorta crossing
over the anterior surface (encircled with sling). Black asterisk indicates tracheal product. Black hashtag indicates the retracted aortic arch.
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continued with both direct endoscopic evaluation and bronchog-
raphy (Fig. 4B and 4C).
After 13 days of intensive care support, the patient was trans-
ferred to her local care center, where similar monitoring was per-
formed. She was on intermittent positive airway pressure support,
tolerating up to 1 hour off device at a time. Evaluation of the air-
way continued according to clinical need and, whilst there was a
mild observed degree of malacia, no intervention was necessary.
At day 15, however, the patient developed ventilatory compro-
mise. During bronchoscopic evaluation, there had been progres-
sion of the tracheal graft narrowing. Clinicians suspected that a
possible acute extrinsic compressive event had taken place (an
intrathoracic hemorrhage was hypothesized). A prolonged respira-
tory arrest ensued, with cerebral hypoxic injury and edema. The
girl’s condition was considered irreversible at 24 hours, and she
died following withdraw of ventilator support with parental
consent.
DISCUSSION
Tracheal replacement is widely proposed as a solution for patients
with end-stage upper airway disease for which conventional treat-
ment strategies currently fail [19]. The complexity of upper airway
disease has meant there has been no single, clear strategy for
replacement. A plethora of potential tracheal scaffolds and surgical
techniques for implantation and/or reconstruction have been
described [20]. Such solutions have included synthetic materials
[8], allogeneic trachea [21], aortic grafts [22] and composite recon-
struction from autologous tissue. The heterogeneous presentation
of tracheal pathology has added to the complexity of the picture,
and it is therefore unsurprising that individual groups have devel-
oped their own methods to treat severe airway compromise.
Tissue-engineered grafts have been used clinically to replace
urogenital tissues, including partial bladder replacement, vagina,
and urethra [12, 23]. Other tissue-engineered solutions include
epidermal [24, 25], corneal [26, 27], vascular [28, 29], and tracheal
grafts [14, 15]. Common to many of these have been the use of
scaffolds that are biomimetic of native tissue and the seeding of
cells normally resident at the target site. To avoid rejection, seeded
cells are generally autologous, that is, derived from patient biop-
sies. Cells are often expanded in vitro until required numbers are
achieved and checked for viability, absence of infection, and reten-
tion of the desired phenotype. Cells are subsequently seeded
onto the scaffold ex vivo in a bioreactor and the construct used as
a transplant graft/organ [30]. Recellularization appears to be par-
ticularly critical for airway grafts, as grafts without cells uniformly
fail to remodel appropriately [31]. The precise role of seeded cells,
particularly multipotent cells such as MSCs, is not known but
hypotheses include participation in repair by repopulating the
graft (e.g., differentiating into chondrocytes), modifying the
regenerative process through altered host immune response (e.g.,
promoting pro-repair “M2” macrophage response) [32], and accel-
erating angiogenesis. Targeted research in each of these areas
should be a priority.
A tissue-engineered graft was chosen for this compassionate
use application due to the observed success of similar grafts used
under emergent conditions for an adult [14] and a young boy [15],
both of whom achieved long-term survival. While postoperative
intervention has been required in both cases in the form of bal-
looning and dilatation, this is not dissimilar to the aftercare
required in conventional airway surgery. Both patients have pat-
ent airways and have been able to return to work and school,
respectively. The methods applied have aimed to replace the air-
way with a “like-for-like” graft that is anatomically and functionally
similar to native trachea and does not require immunosuppres-
sion, both of which are intuitive advantages.
With airway grafts, there has been an increasing emphasis on
the importance of a viable epithelial layer to improve repair and
regeneration [33, 34]. In this case, we were able to deliver epithe-
lial cells to GMP compliance for a tissue-engineered graft. How-
ever, the delivery of autologous cells represented a signiﬁcant
challenge due to the difﬁculties in expanding sufﬁcient numbers of
cells from small samples/biopsies. Subsequent to this clinical case,
we have developed a protocol for the rapid expansion of human
airway epithelial cells that retain basal cell marker expression and
differentiation capacity, potentially overcoming this hurdle [35].
In our previous compassionate tracheal replacement case at
GOSH [36], we used an internal biodegradable stent [37]. This pro-
vided insurance against a reduction in biomechanical integrity, but
we observed an intense inﬂammatory response within the lumen
that contributed to signiﬁcant morbidity during the early postop-
erative period. This was at least in part due to the stent material,
as shown by subsequent experience with stents in children [38].
Also, this earlier graft was not seeded with selected and expanded
epithelial cells and was instead reliant on resected mucosal biop-
sies secured on the luminal surface with a stent. Due to delayed
re-epithelialization, the eventual epithelial covering was thought
Figure 4. Postoperative evaluation of the airway. Endoscopic view of transplanted airway at POD 1 (A) and POD 6 (B). (C): Bronchographic
evaluation at POD 7 with PA (left) and lateral (right) views. Blue arrows show contrast within the margins of the transplanted trachea.
Abbreviations: PA, posteroanterior; POD, postoperative day.
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to be derived from ingrowth of recipient epithelium rather than
from the biopsies [11]. In the case we describe here, time require-
ments permitted autologous cell expansion and seeding in a bio-
reactor. We opted for a non-stented scaffold graft in order to
preserve these cells as far as possible and avoid the morbidity
associated with absorbable stents.
It is reasonable to hypothesize that the biomechanical rigidity
of a tissue-engineered implant in early weeks and months may
reduce as remodeling and revascularization occurs, and that this
process contributed to the severe obstructive event in the present
case. We were unable to conﬁrm this, as postmortem retrieval of
the graft was not possible (declined by request of patient’s rela-
tives). For the same reason, we were unable to conﬁrm whether
the mechanism for acute obstruction was a primary failure of the
graft, severe malacia, or secondary to extraluminal compression.
Nonetheless, the clinical events lead us to recommend stenting of
tracheal grafts for at least the ﬁrst few months following trans-
plantation. More evidence surrounding alterations in biomechani-
cal performance of bioengineered tracheas in relevant in vivo
models or from human trials experience is required. If biomechan-
ical integrity is altered long term, external stenting may also repre-
sent a potential solution. It is noteworthy that previous porcine
studies have not observed such mechanical changes when trans-
planted [31], which may represent inherent differences between
species and/or the fact that in vivo models cannot replicate the
pathology seen in complex airway patients.
To our knowledge, this was the ﬁrst occasion in which a
tissue-engineered trachea was prepared to full clinical standards
(GMP, U.K.). The constituent cells and scaffold, as well as the even-
tual composite seeded graft, were prepared according to validated
standard operating procedures and subject to quality control and
release criteria (an upper threshold for maximum DNA content
after decellularization and absence of detectable HLA class I
expression on decellularized scaffold; sterility of the scaffold,
MSCs, and epithelial cells; absence of detectable endotoxin). As a
result of this case, we have been able to identify areas for
improvement in all areas of preparation and quality control, which
has directly led to the protocols that are now approved by the
MHRA and could inform future clinical trials of tracheal and laryn-
geal tissue-engineered implants. The lessons learned are invalu-
able for those wishing to translate tissue-engineered products for
a range of unmet clinical needs.
There has been debate about the most scientiﬁcally valid and
ethical means of introducing novel surgical technology, including
those involving ATMP, as here [39]. Many countries regulate the
use of novel treatments for compassionate purposes. In the U.K.,
hospitals need speciﬁc licensing, as do the laboratories preparing
the therapeutic product (a specials license). There is some varia-
tion between hospitals regarding local ethical review, but, in gen-
eral, a properly constituted clinical ethics committee needs to
consider the individual case and a dedicated, preferably independ-
ently monitored, consenting process developed. It is also impor-
tant that patients are not approached as research subjects and
that no procedures, such as biopsies and imaging, are performed
that are not strictly required for clinical purposes without full dis-
cussion with and approval from the patient, their family, and
appropriate ethics and regulatory bodies.
We believe reports of both success and failures of compas-
sionate use “ﬁrst-in-human” cases must be combined with pre-
clinical data to build applications to regulatory bodies for clinical
trials authorization (Clinical Trial Authorisation, U.K.; FDA’s
Investigational New Drug Application in U.S.). Conversely, failure
to report interventions performed under compassionate use legis-
lation, especially when outcomes are not favorable, may unfairly
skew the literature and lead to inappropriate conclusions about
safety and potential efﬁcacy. Underreporting of negative or null
outcomes is a major threat to the ﬁeld and there are few incen-
tives to prevent this type of publication bias [40, 41]. We would
advocate a standardized approach to form an international regis-
try to document the application of ATMPs for compassionate use
with registration, analysis, and publication of outcomes a prereq-
uisite for granting of approval.
CONCLUSION
Based on our previous successful experiences, we developed a
tissue-engineered tracheal replacement for a girl with critical tra-
cheal stenosis unsuitable for conventional reconstructive techni-
ques. The graft was prepared to full GMP standards. The early
results were encouraging, as demonstrated by an immediate
improvement in exercise tolerance. However, an acute event,
hypothesized to be acute malacia and/or an intrathoracic bleed,
caused airway obstruction at 3 weeks and resulted in her death.
This experience has permitted us to substantially improve our
GMP and clinical protocols to reduce risk and improve outcomes
for future patients. Speciﬁcally, we advocate the use of indwelling
stents for several months after implantation. Our GMP and clinical
protocols will shape future phase I/II clinical trials of tracheal
replacement.We advocate the formation of an international regis-
try of clinically delivered ATMPs for compassionate use cases.
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